New York, NY – For decades, the presence of a specific type of immune cell, known as regulatory T (Treg) cells, has been a harbinger of grim prognoses in most solid tumors. These cells act as natural "brakes" on the immune system, dampening its ability to mount a robust attack against cancerous invaders. Yet, colorectal cancer (CRC) has long stood as a perplexing exception to this rule, where a higher abundance of Treg cells paradoxically correlates with improved patient survival. This puzzling anomaly has stumped cancer researchers, obscuring crucial insights into effective treatment strategies.
Now, a groundbreaking study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has finally demystified this long-standing paradox. The research, published in the prestigious scientific journal Immunity, reveals that not all Treg cells are created equal. Instead, the team discovered two distinct subtypes of Treg cells within colorectal tumors, each playing opposing roles in disease progression. This pivotal finding not only explains CRC’s unique immune landscape but also illuminates a promising new pathway for immunotherapy, particularly for the vast majority of colorectal cancer patients who currently have limited treatment options. The implications of this discovery could extend beyond CRC, potentially revolutionizing therapies for cancers arising in other "barrier tissues" like the skin, mouth, throat, and stomach lining.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Dr. Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
The Colorectal Cancer Paradox: A Long-Standing Mystery Solved
The human immune system is a sophisticated defense network, constantly vigilant against pathogens and abnormal cells, including cancer. However, to prevent autoimmune diseases, it also possesses built-in mechanisms for self-regulation, ensuring it doesn’t mistakenly attack healthy tissues. Regulatory T cells (Tregs) are central to this delicate balance, maintaining what is known as "immune tolerance." They are essential for preventing allergies, autoimmune conditions, and even for allowing a healthy pregnancy.
In the context of cancer, however, this immune-suppressing function often backfires. Large numbers of Tregs migrating into tumors typically suppress the anti-cancer immune response, allowing tumors to grow unchecked. This detrimental role has been observed across a wide spectrum of cancers, making Treg depletion a tempting, albeit often challenging, therapeutic target.
Colorectal cancer, the second leading cause of cancer-related death when men and women are counted together, according to the American Cancer Society, defied this conventional understanding. For years, clinicians observed a counterintuitive phenomenon: patients with more Tregs in their CRC tumors often experienced better outcomes and longer survival. This perplexing observation highlighted a fundamental gap in the understanding of CRC immunology, suggesting that the role of Tregs in this specific cancer was far more nuanced than previously assumed.
The MSK study, led by first authors Dr. Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dr. Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Dr. Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie, PhD, the study’s other senior author, provides the definitive answer. Their research meticulously dissected the heterogeneity of Treg cells, revealing that the key lies not in their overall quantity, but in their specific functional identities.
A Deeper Look at Treg Cells: Not All Created Equal
The central discovery of the MSK team is that tumor-associated Treg cells are not a monolithic population. Instead, they identified two primary groups, distinguished by their production of a crucial signaling molecule called interleukin-10 (IL-10).
The Protective Power of IL-10-Positive Tregs
One group of Treg cells, termed IL-10-positive Treg cells, was found to actively restrain tumor growth. These beneficial cells exert their anti-cancer effect primarily by reducing the activity of another immune cell type: Th17 cells. Th17 cells produce interleukin-17 (IL-17), a cytokine known to act as a growth signal for tumors, promoting their proliferation and survival. By suppressing Th17 activity, IL-10-positive Tregs effectively cut off a vital supply line for tumor expansion. Importantly, these protective Treg cells were more commonly found in the healthy tissue surrounding the tumor, suggesting they may act as a crucial barrier against unchecked cancer spread.
To confirm their role, researchers conducted experiments where IL-10-positive Treg cells were selectively removed from mouse models of CRC. The result was clear: without these protective cells, tumors grew significantly faster, underscoring their critical role in slowing disease progression.
The Harmful Influence of IL-10-Negative Tregs
In stark contrast, the other group, designated IL-10-negative Treg cells, exhibited a decidedly pro-tumorigenic effect. These cells actively suppress powerful anti-cancer immune defenders, most notably CD8+ T cells. CD8+ T cells are cytotoxic lymphocytes, often referred to as the "soldiers" of the immune system, renowned for their ability to directly identify and destroy cancer cells. By inhibiting these critical effector cells, IL-10-negative Tregs create an immunosuppressive microenvironment within the tumor, allowing cancer cells to evade immune surveillance and thrive. These harmful Treg cells were predominantly located inside the tumor itself, strategically positioned to neutralize immune attacks.
When IL-10-negative Treg cells were eliminated in experimental models, the tumors dramatically shrank. This finding unequivocally demonstrated their detrimental role and highlighted them as a prime target for therapeutic intervention.
Focusing on the Most Common Form of Colorectal Cancer
This discovery carries particular weight for the vast majority of colorectal cancer patients. The MSK study specifically focused on the most prevalent form of the disease, which accounts for approximately 80% to 85% of all colorectal cancers. These tumors are characterized as microsatellite stable (MSS) with proficient mismatch repair (MMRp), meaning their DNA remains relatively stable.
The distinction is crucial because this group of MSS/MMRp cancers typically exhibits a poor response to existing checkpoint inhibitor immunotherapies. While a smaller subset of CRC patients with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd) can often be effectively treated with immunotherapy alone, allowing many to avoid aggressive surgery, chemotherapy, and radiation, the MSS/MMRp majority has largely been left behind by these advancements. The identification of a specific harmful Treg subtype in MSS/MMRp CRC offers a beacon of hope for developing targeted therapies that could finally extend the benefits of immunotherapy to these patients.
From Lab to Clinic: Targeting Harmful Tregs
The findings from Dr. Rudensky’s lab are not merely academic; they suggest a clear and promising path toward improving treatment for most colorectal cancer patients. The research pinpointed a key vulnerability of the harmful IL-10-negative Treg cells: they express high levels of a protein called CCR8. This receptor is found on the surface of these immune-suppressing cells, particularly those located within tumors.
CCR8: A Precision Target for Immunotherapy
The identification of CCR8 as a specific marker for harmful Tregs builds upon earlier pioneering work from Dr. Rudensky’s lab, led by breast cancer surgeon Dr. George Plitas, MD. That research had already shown that CCR8 is highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human cancers. This prior work laid the foundation for the revolutionary idea that antibodies could be engineered to selectively target and eliminate these CCR8-expressing, detrimental Treg cells. The beauty of this approach lies in its precision: it aims to remove only the "bad" Tregs that suppress the immune response, while preserving the "good" beneficial Tregs that are crucial for maintaining immune tolerance in healthy tissues. This selective depletion could unleash the immune system’s full power to attack tumors more effectively, without triggering widespread autoimmune side effects.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky emphasizes, highlighting the global scientific community’s recognition of this strategy’s potential.
Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, testing CCR8-targeting antibodies both as standalone therapies and in combination with existing immunotherapies. The new study strongly reinforces the rationale for deploying this strategy in colorectal cancer and signals its potential applicability across a broader spectrum of malignancies.
"This research shows how important these positive cells are," Dr. Huang notes. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones."
Broader Horizons: Implications for Other Cancers
The MSK team’s investigation extended beyond colorectal cancer, probing a vast dataset of T cells from 16 different cancer types. Their comprehensive analysis revealed that the same crucial division between IL-10-positive and IL-10-negative Treg cells is not unique to CRC. Similar immune patterns were identified in several cancers affecting what are known as "barrier tissues"—those that form interfaces with the external environment. This includes cancers of the skin, mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explains Dr. Mitra, who spearheaded the intricate data analysis for the study and is co-mentored by Dr. Leslie and Dr. Rudensky.
This significant finding suggests that therapeutic strategies designed to remove IL-10-negative Treg cells in colorectal cancer could very well be effective against these other cancers that arise in barrier tissues. This opens up the exciting possibility of a unified, targeted approach to immunotherapy for a broader range of solid tumors, potentially impacting millions of patients worldwide.
The Nuance of Metastatic Disease: A Different Immune Balance
While the study offers profound insights into primary colorectal tumors, it also underscores the complexity of advanced disease. When the researchers examined colorectal cancer that had spread to the liver – a common site for CRC metastasis – they observed a distinctly different immune pattern. In these metastatic tumors, the harmful IL-10-negative Treg cells significantly outnumbered the beneficial IL-10-positive cells. Crucially, unlike primary tumors, removing all Treg cells in this metastatic context actually caused the tumors to shrink.
This result highlights a critical consideration for future treatment strategies: the immune microenvironment can vary dramatically depending on the location and stage of the disease. A "one-size-fits-all" approach may not be optimal, and therapies might need to be tailored to account for both the specific tissue involved and whether the disease is primary or metastatic. This nuanced understanding will be vital in developing truly personalized and effective cancer treatments.
A Legacy of Immunological Insight
This breakthrough is the culmination of more than two decades of dedicated research by Dr. Alexander Rudensky, widely recognized as one of the world’s foremost experts on regulatory T cells. His pioneering work has been instrumental in establishing the fundamental principles of Treg cell biology. His lab’s earlier investigations helped to define how Treg cells are generated, how they exert their regulatory functions, and their profound influence on various physiological processes, including immune tolerance, autoimmune disease prevention, and, critically, cancer development. This latest study not only adds another monumental chapter to his legacy but also directly translates his foundational discoveries into tangible therapeutic potential.
The Research Team, Funding, and Disclosures
The comprehensive study involved a collaborative effort by numerous researchers. Additional authors include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK provided essential technological and analytical support, underscoring the collaborative and cutting-edge nature of the research.
The work received substantial funding from multiple prestigious sources, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-José Kravis Fellowship in Quantitative Biology.
Dr. Rudensky maintains various affiliations with biotechnology and pharmaceutical companies, serving on scientific advisory boards and holding equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor for the Journal of Experimental Medicine and an editorial advisor to Immunity. Importantly, Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8, highlighting the direct translational potential of their scientific endeavors.
Looking Ahead: The Future of Immunotherapy
The MSK study represents a profound leap forward in understanding the complex interplay between the immune system and cancer. By resolving the long-standing colorectal cancer paradox, researchers have not only clarified a fundamental immunological mystery but have also unveiled a precise and actionable therapeutic target. The ability to selectively eliminate harmful immune-suppressing cells, while preserving beneficial ones, holds immense promise for developing more effective and safer immunotherapies. For the millions of patients with common forms of colorectal cancer and potentially other barrier tissue cancers, this discovery heralds a new era of hope, moving closer to a future where cancer treatments are not just powerful, but also exquisitely tailored to the unique immunological landscape of each patient’s disease.
About the Author
